OncoSec Medical Incorporated (NASDAQ: ONCS) stock fell -9.69% on Thursday to $0.45 against a previous-day closing price of $0.50. With 0.22 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.75 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.4987 whereas the lowest price it dropped to was $0.4022. The 52-week range on ONCS shows that it touched its highest point at $20.68 and its lowest point at $0.44 during that stretch. Beta for the stock currently stands at 2.02.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ONCS was down-trending over the past week, with a drop of -13.80%, but this was down by -48.82% over a month. Three-month performance dropped to -65.35% while six-month performance fell -88.51%. The stock lost -97.50% in the past year, while it has lost -73.19% so far this year.
Float and Shares Shorts:
At present, 4.55 million ONCS shares are outstanding with a float of 4.43 million shares on hand for trading. On Apr 27, 2023, short shares totaled 0.13 million, which was 2.96% higher than short shares on Mar 30, 2023. In addition to Dr. Robert H. Arch Ph.D. as the firm’s Pres, CEO & Non-Independent Director, Mr. George Chi C.F.A., CPA serves as its CFO, Exec. VP of Fin., Sec. &Treasurer.
Through their ownership of 5.83% of ONCS’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 4.21% of ONCS, in contrast to 1.49% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in ONCS with 2.32% of the stake, FNY Capital Management LP holds 105,690 shares worth 105,690. A second-largest stockholder of ONCS, The Vanguard Group, Inc., holds 57,066 shares, controlling over 1.25% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in ONCS, holding 25,187 shares or 0.55% stake. With a 1.25% stake in ONCS, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 57,066 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.17% of ONCS stock, is the second-largest Mutual Fund holder. It holds 7,517 shares valued at 6299.0. Fidelity Series Total Market Inde holds 0.02% of the stake in ONCS, owning 1,003 shares worth 841.0.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jan 30, 2023, ONCS reported revenue of $0.00 and operating income of -$9.55M. The EBITDA in the recently reported quarter was -$9.24M and diluted EPS was -$3.52.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ONCS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ONCS analysts setting a high price target of $110.00 and a low target of $110.00, the average target price over the next 12 months is $110.00. Based on these targets, ONCS could surge 24344.44% to reach the target high and rise by 24344.44% to reach the target low. Reaching the average price target will result in a growth of 24344.44% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded ONCS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 3 over the past year. The total number of shares bought during that period was 0 while 607 shares were sold.